Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.
Saved in:
| Title: | Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes. |
|---|---|
| Authors: | Colletta A; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.; Division of Gastroenterology, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States., Cooper KM; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States., Placentino G; Diabetes Clinic, Azienda Sanitaria Locale Verbano Cusio Ossola (ASL VCO), Verbania, Italy., Devuni D; Division of Internal Medicine, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States.; Division of Gastroenterology, UMass Chan Medical School, Division of Internal Medicine, Worcester, MA, United States., Colletta C; Hepatology COQ, Madonna del Popolo Hospital, Omegna, Italy. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 May 15; Vol. 16, pp. 1531295. Date of Electronic Publication: 2025 May 15 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
